Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biovica International AB (publ) (BIOVIC-B.ST)
SEK0.45
+0.04 (+8.41%)
SE STO Healthcare Biotechnology
Address
Dag HammarskjOelds vAeg 54B 752 37
Uppsala, SE
Uppsala, SE
CEO
Anders Rylander
Website
biovica.com
IPO
2017-03-29
ISIN SE0008613731
Description
Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK0.45
+0.04 (+8.41%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
628.5K
Beta
1.09
Float Shares
177.72M
Free Float %
96.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +14.79% | +19.71% | +22.87% | +24.33% | +20.40% | -2.78% | -36.21% | -93.43% | -99.08% | -96.49% | -96.49% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.45
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-7.09
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+55.2% ★ Q2'26: +106.5% (vs Q2'25)
-
EPS growth Biotechnology: +29.7%+68.4% ★ Q2'26: +68.8% (vs Q2'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-491.5% Q2'26: -337.9% (vs Q2'25)
-
EBIT margin Biotechnology: +0.0%-523.5% Q2'26: -375.8% (vs Q2'25)
-
ROIC Biotechnology: -16.1%-346.4% Q2'26: -358.0% (vs Q2'25)
-
Share dilution Biotechnology: -3.4%+153.6% Q2'26: +198.5% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q2'26: -0.07× (vs Q2'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Apr 2017 actual |
Apr 2018 actual |
Apr 2019 actual |
Apr 2020 actual |
Apr 2021 actual |
Apr 2022 actual |
Apr 2023 actual |
Apr 2024 actual |
Apr 2025 actual |
Apr 2026 1 Rev. Ana. 1 EPS Ana. |
Apr 2027 1 Rev. Ana. 1 EPS Ana. |
Apr 2028 1 Rev. Ana. 1 EPS Ana. |
Apr 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
632.0K
est: 6.10M (-89.6%)
|
2.72M
est: 2.70M (+0.9%)
|
3.01M
est: 3.04M (-1.2%)
|
1.67M
est: 1.84M (-9.0%)
|
2.08M
est: 2.54M (-18.2%)
|
2.05M
est: 1.14M (+79.6%)
|
3.38M
est: 10.90M (-69.0%)
|
7.29M
est: 7.24M (+0.6%)
|
8.62M
est: 10.00M (-13.8%)
|
13.20M
13.20M – 13.20M
+32.0% YoY
|
39.60M
39.60M – 39.60M
+200.0% YoY
|
69.10M
69.10M – 69.10M
+74.5% YoY
|
98.00M
98.00M – 98.00M
+41.8% YoY
|
| EBITDA |
-13.02M
est: -6.10M (-113.5%)
|
-15.22M
est: -2.70M (-463.6%)
|
-18.50M
est: -3.04M (-508.2%)
|
-25.65M
est: -1.84M (-1,297.2%)
|
-36.56M
est: -2.54M (-1,340.4%)
|
-53.47M
est: -1.14M (-4,596.9%)
|
-105.96M
est: -10.90M (-872.1%)
|
-119.51M
est: -7.24M (-1,550.0%)
|
-76.22M
est: -10.00M (-662.2%)
|
-13.20M
-13.20M – -13.20M
-32.0% YoY
|
-39.60M
-39.60M – -39.60M
-200.0% YoY
|
-69.10M
-69.10M – -69.10M
-74.5% YoY
|
-98.00M
-98.00M – -98.00M
-41.8% YoY
|
| EBIT |
-14.69M
est: -6.10M (-140.8%)
|
-17.96M
est: -2.70M (-565.0%)
|
-21.52M
est: -3.04M (-607.4%)
|
-29.82M
est: -1.84M (-1,524.4%)
|
-39.33M
est: -2.54M (-1,449.2%)
|
-59.91M
est: -1.14M (-5,162.5%)
|
-110.40M
est: -10.90M (-912.8%)
|
-123.85M
est: -7.24M (-1,609.9%)
|
-85.07M
est: -10.00M (-750.7%)
|
-13.20M
-13.20M – -13.20M
-32.0% YoY
|
-39.60M
-39.60M – -39.60M
-200.0% YoY
|
-69.10M
-69.10M – -69.10M
-74.5% YoY
|
-98.00M
-98.00M – -98.00M
-41.8% YoY
|
| Net Income |
-14.86M
est: -65.94M (+77.5%)
|
-18.06M
est: -79.44M (+77.3%)
|
-21.56M
est: -105.09M (+79.5%)
|
-30.32M
est: -72.62M (+58.3%)
|
-39.48M
est: -103.14M (+61.7%)
|
-60.00M
est: -153.23M (+60.8%)
|
-110.49M
est: -176.64M (+37.4%)
|
-124.82M
est: -398.71M (+68.7%)
|
-87.62M
est: -360.67M (+75.7%)
|
-70.44M
-70.44M – -70.44M
+80.5% YoY
|
-46.96M
-46.96M – -46.96M
+33.3% YoY
|
-23.48M
-23.48M – -23.48M
+50.0% YoY
|
4.47M
4.47M – 4.47M
+119.0% YoY
|
| SGA |
9.67M
est: 104.40M (-90.7%)
|
9.50M
est: 46.21M (-79.4%)
|
11.96M
est: 52.07M (-77.0%)
|
15.39M
est: 31.41M (-51.0%)
|
15.33M
est: 43.45M (-64.7%)
|
59.35M
est: 19.49M (+204.6%)
|
106.69M
est: 186.55M (-42.8%)
|
128.63M
est: 127.66M (+0.8%)
|
85.63M
est: 176.26M (-51.4%)
|
232.66M
232.66M – 232.66M
+32.0% YoY
|
697.97M
697.97M – 697.97M
+200.0% YoY
|
1.22B
1.22B – 1.22B
+74.5% YoY
|
1.73B
1.73B – 1.73B
+41.8% YoY
|
| EPS |
-0.84
est: -0.71 (-17.9%)
|
-1.02
est: -0.86 (-18.9%)
|
-1.14
est: -1.14 (-0.4%)
|
-1.20
est: -0.78 (-53.0%)
|
-1.29
est: -1.11 (-15.8%)
|
-1.96
est: -1.66 (-18.4%)
|
-2.98
est: -1.91 (-56.2%)
|
-2.14
est: -1.70 (-26.0%)
|
-0.95
est: -1.54 (+38.2%)
|
-0.30
-0.30 – -0.30
+80.5% YoY
|
-0.20
-0.20 – -0.20
+33.3% YoY
|
-0.10
-0.10 – -0.10
+50.0% YoY
|
0.02
0.02 – 0.02
+119.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-10 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-09 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-03 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-02 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-06-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-60.25M
OE per share TTM
-0.43
Owner's Yield
-61.24%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
172.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-26.9K
Shares Outstanding
185.17M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anders Moren | Chief Financial Officer | — | male |
| Anders Rylander | President, Chief Executive Officer & Director | — | male |
| Hanna Ritzén | Senior VP of Global Marketing & Business Development | — | female |
| Hector Tamburini | Head of US Laboratory Operations, Regulatory & Quality | — | male |
| Henrik Winther | Senior Vice President of Business Development | — | male |
| Theis Kipling | Chief Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIOVIC-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
